Cannabis Law Report

AUGUST 17, 2021

–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. Orphan drug designation provides certain benefits, including market exclusivity upon regulatory approval, if received, exemption of FDA application fees and tax credits for qualified clinical trials. RADNOR, Pa.–(BUSINESS

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

MAY 31, 2022

The only psychedelic drug that is approved (outside of clinical trials) for psychiatric use—as opposed to anesthesia—through the traditional medical system is Ketamine. 2022 Active FDA Clinical Trials and State-Regulated Systems. Active FDA Regulated Clinical Trials*. On March 5, 2019, the U.S. Schedule I.

Clinical Trials 52

Clinical Trials Legalization Therapy Decriminalization 52

Cannabis Law Report

NOVEMBER 19, 2021

It has been designated a Breakthrough Therapy by the FDA and the results of our pivotal Phase 3 clinical trial were published in Nature Medicine or profiled on the front page of The New York Times. MAPS PBC strives to establish a supportive, equitable and accessible work environment. European Regulatory Lead Executive Summary.

Clinical Trials 52

Clinical Trials Research and Development Therapy Compliance 52

Cannabis Law Report

NOVEMBER 19, 2021

It has been designated a Breakthrough Therapy by the FDA and the results of our pivotal Phase 3 clinical trial were published in Nature Medicine or profiled on the front page of The New York Times. MAPS PBC strives to establish a supportive, equitable and accessible work environment. Key Responsibilities. Position Requirements.

Research and Development 52

Research and Development Clinical Trials Therapy Pharmaceutical 52

Cannabis Law Report

APRIL 21, 2022

Commercialization & Patient Access · Any City, Any State, California. It has been designated a Breakthrough Therapy by the FDA and the results of our pivotal Phase 3 clinical trial were published in Nature Medicine and profiled on the front page of The New York Times. About MAPS Public Benefit Corporation (MAPS PBC).

Advocacy 52

Advocacy Therapy Clinical Trials Environment 52

Cannabis Law Report

AUGUST 2, 2021

SAN DIEGO–(BUSINESS WIRE)– Radicle Science , a transformative healthtech B-corp validating natural products for the first time, announces the launch of the Radicle ACES (Advancing CBD Education and Science) study. brands, including Lord Jones. We are delighted to have Lord Jones involved in the Radicle Sciences’ ACES study.

CBD 105

CBD Data Sleep Clinical Trials 105

Cannabis Law Report

JANUARY 4, 2022

AUSTIN, Texas–(BUSINESS WIRE)–Anebulo Pharmaceuticals, Inc. Since March 2019, Mr. Allen has served as Chief Business Officer of Ambrx Biopharma Inc. Simon is a tremendous leader with significant commercial and business development experience, which are the most relevant skills for Anebulo at this stage.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Cannabinoids 52

Cannabis Law Report

JANUARY 19, 2022

GMP psilocybin previously manufactured by Psygen personnel in collaboration with a licensed dealer using Psygen’s methods has already been used in clinical trials for development of therapeutic products. “A primary application for psychedelics is to support psychotherapy for treatment of mental health conditions.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Conditions 52

Cannabis Law Report

MAY 12, 2022

Lophora has previously secured grant funding from the BioInovation Institute (Novo Nordisk Foundation) and continues to characterise its lead candidates, aiming to initiate clinical trials in 2023. Broad collaboration with Lophora will further strengthen Beckley Psytech’s world class management and R&D team.

Medicine 52

Medicine Research and Development Clinical Trials Treatment 52

Cannabis Law Report

SEPTEMBER 20, 2021

provides Heritage and subsidiary Opticann the benefits of offering patients access to safe, convenient, and effective CB4 products developed on trusted technology platforms. TORONTO–(BUSINESS WIRE)–Heritage Cannabis Holdings Corp.

Clinical Trials 52

Clinical Trials Pharmaceutical Data Patients 52

Cannabis Law Report

SEPTEMBER 14, 2021

This alliance is just the first step in a larger movement to co-create a future where consumers have access to trusted cannabinoid products that fully deliver on their potential to help people live healthier, fuller lives.”. About Radicle Science.

Extraction 52

Extraction Research and Development Clinical Trials CBD 52

Cannabis Law Report

SEPTEMBER 1, 2021

The company recently became the industry’s first firm to list on the NYSE American exchange and their psilocybin clinical trial for depression is making excellent progress. His background is a mix of cognitive psychology, clinical psychology and computer science. On a Trip: LSD (Lysergic Acid Diethylamide).

Research and Development 102

Research and Development Therapy Clinical Trials Pharmaceutical 102

Cannabis Law Report

DECEMBER 1, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, today announced that it will participate in two investor conferences during the month of December 2021. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

DECEMBER 21, 2021

Numinus also made important alliances in 2021, particularly with the Multidisciplinary Association for Psychedelic Studies (MAPS) on its compassionate access trial for MDMA-assisted therapy. While its psilocybin and MDMA trials progress, the company is expanding its psychedelics research laboratory.

Clinical Trials 52

Clinical Trials Therapy Treatment DEA 52

Cannabis Law Report

MARCH 29, 2022

Former Moderna Vice President and Managing Director for North America recruited to prepare MAPS PBC for patient access and commercialization of the first psychedelic-assisted therapy anticipated to be approved by the FDA. has joined MAPS PBC as Head of Market Access. Amy Emerson , CEO, MAPS PBC. Theresa Gorenc, M.P.H. ,

Therapy 52

Therapy Pharmaceutical Clinical Trials Access 52

Cannabis Law Report

NOVEMBER 16, 2021

Believed to be the only IND application ever cleared by the FDA for a Phase 2 trial of a patented drug for delaying aging. Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

NOVEMBER 19, 2021

It has been designated a Breakthrough Therapy by the FDA and the results of our pivotal Phase 3 clinical trial were published in Nature Medicine or profiled on the front page of The New York Times. MAPS PBC strives to establish a supportive, equitable and accessible work environment. Deputy General Counsel Executive Summary.

Therapy 40

Therapy Compliance Compliance Clinical Trials 40

Cannabis Law Report

SEPTEMBER 20, 2021

KWC is the largest national chain of ketamine infusion clinics in the United States and will add to Delic’s existing portfolio of two clinics operated by Ketamine Infusion Centers in California and Arizona , cementing its position as the leading and largest health provider in the country. employees bringing a wealth of industry ?

Treatment 52

Treatment Media Research and Development Patients 52

Cannabis Law Report

SEPTEMBER 14, 2021

13, 2021 /PRNewswire-PRWeb/ — A host of scientific research and clinical trials around the world are affirming the remarkable effectiveness of psilocybin, the principal psychoactive component of “magic mushrooms,” in the treatment of a variety of medical conditions, including depression, anxiety, addiction, and PTSD.

Clinical Trials 52

Clinical Trials Events Medicine Therapy 52

SpeedWeed

AUGUST 4, 2021

She moved into the television business with a major Australian network where she quickly was promoted into the position of National Travel Manager. At the age of 29, she left production and started a hospitality business which she built up into one of the best-known entertainment restaurants in Sydney. Courtesy of Sharon Bentley.

Chronic Pain 52

Chronic Pain Research and Development Medicine Supply Chain 52

Cannabis Law Report

DECEMBER 7, 2021

The listing on the FSE enables Labat Healthcare, access to capital from retail and institutional investors in international markets. We expect that the funding will enable the business to successfully navigate tough South African trading conditions and secure a prime spot for the business in the growing cannabis sector,” Maasdorp adds. “We

Clinical Trials 52

Clinical Trials Medicine Cannabis Pharmaceutical 52

Cannabis Law Report

NOVEMBER 23, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. Expands intellectual property portfolio for lead drug candidate MYMD-1 to 12 U.S.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Chronic Pain 52

Cannabis Law Report

JANUARY 5, 2022

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. Expands intellectual property portfolio for lead drug candidate MYMD-1 to 3 U.S.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

Cannabis Law Report

JULY 6, 2021

We look forward to Dr. Johnson’s expertise as we expand our mental health analytical platform and enter clinical trials.” This empowers patients, healthcare providers, and payers to address a wide range of conditions through high quality, safe, and effective data-driven involvement with intelligent and accessible tools.

Research and Development 97

Research and Development Wellness and Beauty Clinical Trials Therapy 97

Cannabis Law Report

MARCH 3, 2022

If everything works out in the production and research phase, there is a clause in the license that will allow it to be expanded to clinical trials. The eventual trials would target PTSD, addiction, alcoholism, depression, and anxiety. This would add to the wave of research beginning in the U.S. and Europe. ” Hon.

Research and Development 52

Research and Development Medicine Clinical Trials Microdosing 52

Cannabis Law Report

DECEMBER 17, 2021

DUBLIN–(BUSINESS WIRE)–The “22q11.2 deletion syndrome clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases. Access and Reimbursement Scenario.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Therapy 52

Cannabis Law Report

DECEMBER 14, 2019

In October, some Canadian firms adjusted their global expansion plans in Australia due to the conditions seen in the cannabis industry. Clinical stage CBD company Botanix Pharmaceuticals (ASX: BDA ) works on using cannabidiol (CBD) in its treatment of skin conditions including acne, psoriasis, dermatitis and rosacea.

Pharmaceutical 98

Pharmaceutical Patients Clinical Trials Hemp 98

The Cannigma

DECEMBER 12, 2022

And while most psychedelics are currently illegal in the United States and around the world, researchers are exploring their use in medicine to treat conditions such as depression, PTSD, addiction, anxiety, OCD, migraines, end of life acceptance of mortality, and eating disorders. Now, psychedelic research is booming.

History 119

History Microdosing Research and Development Clinical Trials 119

Veriheal

AUGUST 31, 2020

Add onto that the difficulty of these unprecedented times, as a minority-owned business, we’re making it our priority to pay it forward and invest in the future leaders of cannabis who will break barriers and pave the way for innovation in this burgeoning industry. . About Clinton: Clinton is an undergraduate student studying business.

Research and Development 117

Research and Development Education Agriculture Patients 117

Cannabis Law Report

JANUARY 20, 2022

Business combination with Silver Spike Acquisition Corp. Eleusis pioneers the development of psychedelic drug candidates in the life sciences space, with the goal of transforming psychedelics into broadly accessible medicines. Currently, its managed clinics provide access to FDA-approved drug therapies like SPRAVATO (esketamine).

Therapy 52

Therapy Research and Development Business Access 52

Cannabis Law Report

OCTOBER 15, 2021

The final two license holders will be selected based on the strength of their business plans, and on the product quality and consistency of three trial crops. Xebra’s unique and intended business model, mitigates risk by partnering with licensed small cultivators, rather than incurring costly land ownership and leases.

Seed-To-Sale 52

Seed-To-Sale Cultivation Clinical Trials Cannabinoids 52

Cannabis Law Report

JUNE 9, 2022

The bill would expand patients’ access to the necessary treatment for more than 50 conditions, including cancer and post-traumatic stress disorder (PTSD), neurological diseases, and chronic pain of neuropathic origin.

Seed-To-Sale 52

Seed-To-Sale Legalization Cultivation Medicine 52

Cannabis Law Report

APRIL 10, 2019

In November, UK law changed to allow clinicians to prescribe medical cannabis under limited conditions. Is he aware that in other jurisdictions a range of conditions qualify for treatment with cannabis oil and related products, including cancer, AIDS, muscular dystrophy, Crohn’s disease, epilepsy, Parkinson’s disease and arthritis?

Clinical Trials 51

Clinical Trials Epilepsy Medicine Research and Development 51

Cannabis Law Report

JULY 25, 2022

Reporter Elise Worthington also investigates the dark side of this form of therapy where disturbing cases of abuse and malpractice are emerging in both clinical trials and the underground. There’s now pressure in the industry to downplay the negative stories by those who stand to profit from the business of psychedelics.

Medicine 52

Medicine Therapy Research and Development Business 52

Cannabis Law Report

APRIL 13, 2022

Complementary businesses combine to create a preeminent North American platform with operations spanning 13 wellness clinics, four research sites and one bioanalytical laboratory. Clinics will also offer family and couples counselling, as well as in-person and virtual group therapy for expanded access to innovative treatments.

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

Cannabis Law Report

OCTOBER 26, 2019

One such circumstance is a clinical trial. A clinical trial in Australia must have an Australian sponsor (whether it be an individual (e.g., Two of the avenues for supply of UTGs for clinical trials are the Clinical Trial Exemption (CTX) Scheme and the Clinical Trial Notification (CTN) Scheme.

Clinical Trials 45

Clinical Trials Medicine Research and Development Compliance 45

MGC Pharma

FEBRUARY 20, 2018

The Top Medical Cannabis Research of 2017 A word from Ron Lipsky, Manager of Business Development and International Relations at MGC Pharmaceuticals MGC Pharma is still riding off the success of 2017 as we progress into 2018, with many exciting developments on the horizon. Notably, 41% of the Cannabis users stopped using opioids altogether.

Research and Development 100

Research and Development Clinical Trials Patients Chronic Pain 100